Ecuador ARCSA Regulatory System: Legal Framework and the 2026 Reform

1. Key takeaways

Medical devices for human use in Ecuador are regulated by a single authority, the National Agency for Health Regulation, Control and Surveillance (ARCSA), under a mandatory health registration system known as the Registro Sanitario. Registration certificates are valid for 5 years and can be renewed for an equivalent term. The chain of regulatory authority follows a three-layer structure: the Ley Organica de Salud grants the powers, Decreto Ejecutivo 1290 creates the agency, and ARCSA resolutions define the procedures. From January 28, 2027 onward, the current core regulation will be replaced in its entirety by Resolucion ARCSA-DE-2026-003-DASP, and manufacturers in the Chinese mainland should prepare in parallel under both the outgoing and incoming regimes.

2. Legal basis

Entry into force: the final article of the new regulation states that it enters into force once a period of 9 months counted from the date of signature has elapsed, without prejudice to its publication in the official gazette. The signature date is 2026-04-28, so the effective date is 2027-01-28. The effective date is anchored to the signature date and is independent of the gazette publication date.

3. Expert insights

Insight one: the three-layer authorization chain determines who can change the rules. The Ley Organica de Salud only grants powers; Article 10 of Decreto Ejecutivo 1290 delegates to ARCSA the authority to issue technical regulations, standards and procedures; and what actually specifies which documents must be submitted, how long review takes, and in which cases applications are returned are ARCSA-level resolutions. This means that Ecuadorian registration rules change frequently but at a low administrative tier, with no legislative procedure required. When tracking Ecuadorian requirements, manufacturers in the Chinese mainland should focus on ARCSA resolutions and their companion instructivos.

Insight two: ARCSA jurisdiction covers both products and establishments, which is the point most often left out of planning. The new regulation governs not only product registration (Articles 5 to 59) but also establishment obligations: operating permits (Article 60), good manufacturing practices (Article 61), ISO 13485 registration (Articles 62 and 63), and post-registration controls and inspections (Articles 64 to 69). Product compliance and channel compliance are two independent lines of obligation, and failing either one prevents goods from moving through the market.

Insight three: the change from the old regulation to the new one is a wholesale replacement, not a revision layered on top of revisions. The first item of the repealing provisions (DISPOSICIONES DEROGATORIAS) expressly lists the repeal of ARCSA-DE-026-2016-YMIH together with its four amendments (ARCSA-DE-004-2017-CFMR, ARCSA-DE-033-2017-FMRH, ARCSA-DE-030-2018-JCGO and ARCSA-DE-2023-001-VSVZ), and the second item repeals ARCSA-DE-2023-033-AKRG.

Insight four: the new regulation expressly repeals ARCSA-DE-030-2018-JCGO, whose publication date is 2019 rather than 2018. The repealing provisions list the gazette issue and date as Registro Oficial No. 416 (29-01-2019). Chinese-language materials commonly record it as a 2018 instrument; the official listing prevails.

Insight five: the transition period carries an instructivo gap risk. Nine months separate signature from entry into force, and the current regulation remains valid in the interim, but ARCSA must issue companion instructivos under the transitional provisions before the classification rules and the tiered technical documentation requirements can actually operate. Where instructivos have not yet been issued, for example the precise boundary of free commercialization for low-risk devices, the practical estimate for enforcement will remain unclear in the early period after entry into force.

4. Practical recommendations

1. Treat 2027-01-28 as a project milestone and build the schedule backward from it: adapting dossiers to the new regulation, including classification alignment and finer technical documentation, itself requires a preparation window of 2 to 3 months.
2. Establish a two-layer tracking mechanism covering resolutions and instructivos: resolutions set the framework, instructivos set the requirements, and both are indispensable.
3. Keep a ledger of applications submitted before 2027-01-28: record the submission date, the file number and the applicable regulation version, so that the applicability of the old rule can be asserted during the transition.
4. Plan product and channel compliance in parallel: a registration certificate is only the entry ticket; the certificate holder must also hold a valid operating permit and the corresponding good practice certification.
5. Document every classification conclusion: Article 22 of the new regulation requires classification according to the ARCSA instructivo, so borderline products should retain written justification for their level.

5. Verification checklist

• □ The risk class (I/II/III/IV) and the device type (DMA/DMI/DMNI/DMDIV) of each target product have been confirmed
• □ The intended pathway, standard registration or simplified registration, has been confirmed
• □ The proposed license holder has been confirmed as an entity established in Ecuador holding a valid operating permit
• □ The project schedule has been checked against the 2027-01-28 effective date
• □ A tracking list of ARCSA resolutions and companion instructivos has been established
• □ The certification chain for the free sale certificate and the letter of authorization has been planned
• □ The language of the technical documentation meets the Article 12 requirement of Spanish or English

Regulatory information verified as of October 29, 2026

GRZAN core service lines

1. Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
2. Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
3. Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
4. Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

• Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
• Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
• Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
• Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation